Thoracic Oncology Program »  Meet the Team »  Radiation Oncologists »  Steve Braunstein, M.D., Ph.D.
Steve Braunstein, M.D., Ph.D.

Steve Braunstein, M.D., Ph.D.

Assistant Professor
Department of Radiation Oncology

Contact Information

Helen Diller Family Comprehensive Cancer Center
1600 Divisadero Street, Box 1708
San Francisco, California 94143-1708
Phone: 415-353-7175
Fax: 415-353-9883
yoms@radonc.ucsf.edu
Open Popup
  • 1987-91, Rice University, Houston, TX,  B.A.  French
  • 1993-02, University of Pennsylvania, Ph.D. English
  • 1995-02, University of Pennsylvania, M.D., Medicine
  • 2002-2003 M.D. Anderson Cancer Center, Intern, Medicine/Surgery
  • 2003-2007 M.D. Anderson Cancer Center, Resident, Radiation Oncology 
  • American Board of Radiology
  • Thoracic Oncology Program
  • Head and Neck Oncology Program
  • Visible Tumor and High-Risk Skin Cancer Program
  • Department of Radiation Oncology
  • Brachytherapy
  • Bronchioloalveolar Carcinoma (BAC)
  • Chemoradiation
  • CyberKnife irradiation for lung and skull base
  • Electron beam and orthovoltage irradiation
  • External-beam radiation therapy
  • Head & Neck Cancer
  • Hyperthemia
  • Intensity-modulated radiation therapy
  • Non-Small Cell Lung Cancer
  • Small-Cell Lung Cancer
  • Advanced imaging and radiation planning
  • Head and neck and lung cancers
  • Image-guided and adaptive radiation therapy
  • Outcomes and quality of life
  • Radiation in combination with chemotherapy and targeted agents
  • Radiation sensitizers and protectors

In lung cancer, Dr. Yom has conducted research quantifying the risks of pneumonitis and esophagitis when chemotherapy and radiation are given simultaneously. Her research findings were important in establishing the early use of intensity-modulated radiation therapy for lung cancer in combination with 4-dimensional CT-based planning. She has particular expertise in the delivery of chemoradiation therapy for advanced-stage lung cancer, and also the delivery of non-invasive stereotactic CyberKnife radiation for early-stage lung cancer. Her hope is that better understanding of radiation toxicities will permit higher treatment doses, increase the rate of cure and improve patient quality of life. She is strongly committed to research that will lead to more effective, less toxic, and more highly individualized therapy for patients.

Dr. Yom is an investigator on many research studies in head and neck and lung cancer at UCSF, including trials related to to image-guided radiation, head and neck patients' quality of life, and combinations of novel systemic agents with radiation therapy. She is especially interested in improved clinical and translational prognostic models in order to provide more effective and individualized therapy. It is hoped that the reduction of toxicities, both through technical and biologic means, will improve patients' quality of life and potentially enable physicians to deliver more intelligently targeted radiation and chemotherapy doses in search of a better chance of cure. She believes in multidisciplinary management and a unified, team-oriented approach to patient care

  1. Xie J, Yoon YW, Yom SS, Chung JM. Norepinephrine Rekindles Mechanical Allodynia in Sympathectomized Neuropathic Rat. Analgesia 1995;1(2):107-113.
  2. Rosenthal DI, Yom SS, Liu L, Machtay M, Algazy K, Weber RS, Weinstein GS, Chalian AA, Miller LK, Rockwell K Jr, Tonda M, Schnipper E, Hershock D. A Phase I Study of SPI-077 (Stealth® Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer. Investigational New Drugs 2002;20(3):343-349.
  3. Yom SS, Busch TM, Friedburg JS, Smith D, Wileyto EP, Mick R, Glatstein E, Hahn SM. Serum Cytokine Elevations in Mesothelioma Patients Treated with Pleurectomy or Extrapleural Pneumonectomy and Adjuvant Intraoperative Photodynamic Therapy. Photochemistry and Photobiology 2003; 78(1):75-81.
  4. de Crevoisier R, Ammor A, Court B, Wibault P, Chirat E, Fizazi K, Theodore C, Yom SS, Haie-Meder C. Bladder-Conserving Surgery and Interstitial Brachytherapy for Lymph Node Negative Transitional Cell Carcinoma of the Urinary Bladder: Results of a 28-year Single Institution Experience. Radiotherapy and Oncology 2004;72(2):147-157.
  5. Yom SS, Rashid A, Rosenthal DI, Weber RS, El-Naggar AK. Comparative Genetic Analysis of Intestinal and Seromucinous Sinonasal Adenocarcinomas: Distinct and Common Alterations from Primary Colorectal Carcinomas. Modern Pathology 2005;18(3):315-319.
  6. Yom SS, Machtay M, Biel MA, Sinard RJ, El-Naggar AK, Weber RS, Rosenthal DI. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. American Journal of Clinical Oncology 2005 Aug;28(4):385-392.
  7. Yom SS, Rosenthal DI, El-Naggar AK, Kies MS, Hessel AC. Merkel Cell Carcinoma of the Tongue and Head and Neck Oral Mucosal Sites.  Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2006;101(6):761-768.
  8. Yom SS, Morrison WH, Ang KK, Rosenthal DI, Perkins GH, Wong P-F, Garden AS. Two-Field Versus Three-Field Irradiation Technique in the Postoperative Treatment of Head and Neck Cancer. International Journal of Radiation Oncology, Biology, Physics 2006;66(2):469-476.
  9. Yom SS, Liao Z, Liu H, Liu HH, Tucker SL, Hu C-S, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial Evaluation of Treatment-Related Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 2007;68(1):94-102.
  10. Yom SS, Frija EK, Mahajan A, Chang E, Klein K, Shiu A, Ohrt J, Woo SY. Field-in-Field Technique with Intrafractionally Modulated Junction Shifts for Craniospinal Irradiation. International Journal of Radiation Oncology, Biology, Physics 2007;69(4):1193-1198.
  11. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY, Yom SS, Phillips TL, Quivey JM. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 2008;113(3):497-507.
  12. Vitolo V, Millender LE, Quivey JM, Yom SS, Schechter NR, Jereczek-Fossa BA, Milani F, Orecchia R, Xia P. Assessment of Carotid Artery Dose in the Treatment of Nasopharyngeal Cancer with IMRT Versus Conventional Radiotherapy. Radiotherapy and Oncology. 2008 Oct 14.
  13. Jin H, Tucker SL, Liu HH, Wei X, Yom SS, Wang S, Komaki R, Chen Y, Martel MK, Mohan R, Cox JD, Liao Z. Dose-Volume Thresholds and Smoking Status for the Risk of Treatment-Related Pneumonitis in Inoperable Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy. Radiotherapy and Oncology. 2008 Oct 18.
  14. Hwang AB, Bacharach SL, Yom SS, Weinberg VK, Quivey JM, Franc BL, Xia P. Can Positron Emission Tomography (PET) or PET/Computed Tomography (CT) Acquired in a Nontreatment Position Be Accurately Registered to a Head-and-Neck Radiotherapy Planning CT? International Journal of Radiation Oncology, Biology, Physics. 2008 Dec 10.

X